Melius Pharma
Sweden - StockholmPharmaceutical
Focus: Melius Pharma is a Swedish public-stage pharmaceutical company focused on developing treatments for interstitial lung disease, specifically idiopathic pulmonary fibrosis. The company operates with a lean pipeline and is in early-stage clinical development.
Profile data last refreshed 17h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
8+3 this month
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Should You Work at Melius Pharma?
AI assessmentEarly-stage specialty play with respiratory focus and emerging commercial momentum—suitable for career builders willing to accept thin pipeline and execution risk for rare-disease impact.
Why Work Here
- Rare disease focus on IPF offers deep specialization and potential for meaningful clinical impact in an underserved therapeutic area.
- Early-stage pipeline (Phase 2) provides opportunity to influence drug development strategy and see clinical progression in real-time.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (1)
NCT05983471Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Phase 2Help build intelligence for Melius Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.